David L. Nelson

机构：Eli Lilly (United States)

发表论文 123 篇 · 总被引 4607 次 · h-index 41

代表论文

• Preclinical pharmacological profile of the selective 5-HT 1F receptor agonist lasmiditan (2010 · Cephalalgia · 被引 214)
• Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome (1995 · Nature Genetics · 被引 161)
• Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system (2004 · Pharmacology & Therapeutics · 被引 149)
• Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine (1997 · Life Sciences · 被引 140)
• Radiographic absorptiometry for bone mineral measurement of the phalanges: precision and accuracy study. (1994 · Radiology · 被引 119)
• Development of Fluorine-18-Labeled 5-HT1AAntagonists (1999 · Journal of Medicinal Chemistry · 被引 116)